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Risk Factors Associated with the Severity of 
Thyroid-Associated Orbitopathy in Korean Patients
Ji Hwan Lee, Sang Yeul Lee, Jin Sook Yoon
The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Purpose: The purpose of this study is to identify risk factors for severe thyroid-associated orbitopathy (TAO) and 
compressive optic neuropathy in Korean patients.
Methods: This study was a retrospective comparative case series. All TAO patients who were first seen at our in-
stitution between 2005 and 2009 and who had follow-up periods of at least 6 months were included. Patients 
were divided into mild or moderate and severe TAO groups. Cases were also segregated based on the presence 
or absence of optic neuropathy. Demographics, smoking status, comorbidities, thyroid hormonal status, thyroid 
autoantibody levels, and clinical presentations were assessed. 
Results: A total of 99 patients (83 with mild to moderate courses and 16 with severe courses; 90 without optic neuro-
pathy and 9 with optic neuropathy) were included in this study. On multiple logistic regression analysis, smoking 
status was a predictive risk factor for a severe course of TAO and the development of optic neuropathy (odds ra-
tios = 6.57 and 10.00, respectively). Other factors such as age, gender, free T4 level, thyroid binding-inhibiting 
immunoglobulin, and a history of diabetes were not predictive of severe TAO or optic neuropathy. 
Conclusions: Although various factors may influence the severity of TAO and the development of optic neuropathy, 
this study showed that smoking was a risk factor for severe TAO and the development of optic neuropathy. 
Therefore, it is important for patients with Graves’ disease to refrain from smoking. Frequent and careful ob-
servation should also be performed in current smokers, as TAO patients who smoke are susceptible to a severe 
course and/or optic neuropathy.
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Thyroid-associated orbitopathy (TAO) is an autoimmune 
disorder that poses a major clinical and therapeutic challenge. 
The clinical manifestations range from mild findings such 
as tearing, photophobia, and conjunctival injection, to more 
significant findings including proptosis, diplopia, exposure 
keratopathy, and vision loss from compressive optic 
neuropathy. In the majority of patients, ocular involvement 
is not severe and is self-limiting, but 3 to 5% of patients 
have severe and progressive ocular manifestations [1]. 
Severe TAO represents a complex therapeutic challenge 
and approximately one-third of patients are not satisfied 
with their therapeutic outcome at the end of follow-up [2]. 
The onset and progression of TAO are influenced by several 
factors that are potentially modifiable such as cigarette 
smoking, thyroid dysfunction, and choice of treatment mo-
dalities for hyperthyroidism [3-9]. The objective of this 
study was to identify Korean patients at increased risk of a 
severe course of TAO and compressive optic neuropathy. In 
this study, we used multivariate logistic regression analysis 
to compare possible risk factors and various clinical varia-
bles between patients with mild to moderate courses and se-
vere courses of TAO and also between patients with and 
without optic neuropathy. 
Materials and Methods
Enrollment was restricted to patients who were initially 
seen for TAO at our institution between 2005 and 2009 with-
in 6 months after initial onset and who were followed-up for Korean J Ophthalmol Vol.24, No.5, 2010
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A
Fig. 1. The binocular single visual field test (A) and Hess screen (B) of 
a patient with severe restrictive myopathy causing constant diplopia 
within 30 degrees.
B
at least 6 months. Ninety-nine patients were eligible for 
analysis. This study complied with the policies of the local 
Institutional Review Board. 
The diagnosis of TAO was based on the presence of typical 
clinical features of the disease, including eyelid retraction, 
proptosis, impaired motility, an increase in intraocular pres-
sure on upward gaze, one or more enlarged extraocular mus-
cles, and increased intraorbital fat on computed tomography 
scans. In this study, a mild course of TAO was defined as 
proptosis less than 21 mm with no or only intermittent dip-
lopia without optic nerve involvement. Moderate TAO was 
defined as proptosis between 21 mm and 23 mm with inter-
mittent diplopia and no optic nerve involvement [1]. Patients 
were judged to have a severe course of TAO if they had, in 
the worse eye, either motility impairment causing constant 
diplopia within 30 degrees by the binocular single visual 
field test and the Hess screen (Fig. 1); or proptosis greater 
than 23 mm or with a difference between eyes of more than 5 
mm by Hertel exophthalmometry, causing serious exposure 
keratopathy (Fig. 2); or compressive optic neuropathy (Fig. 3). 
Optic neuropathy was diagnosed if more than two of the fol-
lowing symptoms and signs were present: acutely reduced 
vision, abnormal color contrast, relative afferent pupillary 
defect (RAPD), visual field defect by Humphrey visual field 
testing, disc edema and swelling, or apical crowding of the 
extraocular muscles on a computed tomography scan.  
Details on patient demographics including age, sex, prior 
history of hyperthyroidism, onset of TAO associated with 
thyroid disease, comorbidities such as diabetes, hyper-
tension, and myasthenia gravis, and smoking status were 
recorded. 
All patients were examined at least twice (every 3 months) JH Lee, et al. Risk Factor Analysis Associated with the Severity
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A
Fig. 2. Photograph (A), axial (B), and coronal computed to-
mography scans (C) of a patient with unilateral proptosis, 
with a difference of more than 5 mm by Hertel exoph-
thalmometry, causing exposure keratopathy.
B C
A B
Fig. 3. Photograph (A), axial (B), and coronal computed to-
mography scans (C) of a patient with bilateral compressive 
optic neuropathy. 
C
after presentation. At each visit, the serum free T4 level (nor
mal 0.73-1.95 ng/dL) and thyroid binding-inhibiting im-
munoglobulin (TBII, positive when more than 10 U/L) level 
were measured. Eye manifestations were assessed using the 
following parameters: visual acuity, intraocular pressure, 
presence of lid retraction, and proptosis as measured by 
Hertel exophthalmometry. Ocular horizontal and vertical 
ductions were judged on a subjective scale of 0 to -4. The de-Korean J Ophthalmol Vol.24, No.5, 2010
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Table 1. Comparison of demographic, clinical, and biochemical features between patients with mild to moderate courses 
and severe courses of thyroid-associated orbitopathy
Mild to moderate course (n = 83) Severe course (n = 16) p-value
Age (yr)       41 ± 14    49 ± 10 0.007
Male    17/83 (20.5)    7/16 (43.8) 0.060
Follow-up period for TAO (mon)       19.7 ± 20.1   19.4 ± 8.1 0.967
Initial fT4 level ≥3.0 ng/dL     21/70 (30.0)     3/14 (21.4) 0.748
Positive TBII (>0 U/L)     52/60 (86.7)     9/10 (90.0) 1.000
Comorbidity 
    Diabetes
    Hypertension
  2/83 (2.4)
  3/83 (3.6)
    3/16 (18.8)
    2/16 (12.5)
0.029
0.183
Current smoker     16/83 (19.3)     8/16 (50.0) 0.021
Exophthalmos (mm)    18.2 ± 2.7    20.0 ± 3.5 0.029
Lid retraction   48/83 (57.8)    9/16 (56.3) 1.000
Gorman score ≥2     14/82 (17.1)   10/16 (62.5) <0.001
Restrictive myopathy ≥-3     2/83 (2.4)     4/16 (25.0) 0.006
Clinical activity score ≥3  
Clinical activity score 
       12 (14.5)
    1.1 ± 1.2
         9 (56.3)
      2.8 ± 2.2
<0.001
0.007
Values are presented as mean ± SD or number/total number (%).
TAO = thyroid-associated orbitopathy; TBII = thyroid binding-inhibiting immunoglobulin.
gree of diplopia was assessed objectively by the binocular 
single vision test and subjectively by the Gorman score: 
grade 0, no diplopia; 1, intermittent; 2, inconstant (gaze 
evoked); and 3, constant diplopia in primary gaze or while 
reading [10]. Disease activity was evaluated using the 
7-point modified formulation of the clinical activity score by 
Mourits et al. [11,12]. In patients with reduced visual acuity, 
the Ishihara color test, the light pupil reflex test, fundus ex-
amination, the Humphrey visual field test, and an orbital 
computed tomography scan were performed to diagnose op-
tic neuropathy. 
In patients with compressive optic neuropathy, we used in-
travenous methylprednisolone (1 g per day for 3 days) and an 
oral prednisolone taper thereafter. If vision did not return to 
normal or abnormal Ishihara test results, an RAPD, or visual 
field defects persisted, then surgical decompression was 
advised. In patients with a severe active stage (clinical activ-
ity score ≥3) without evidence of optic neuropathy, oral pre-
dnisolone was given for 3 months in decreasing doses: 60 mg 
for the first 2 weeks, 40 mg for 2 weeks, 30 mg for 4 weeks, 
and 20 mg for 4 weeks. Although intravenous glucocorti-
coids are known to be more effective than oral steroids [13], 
oral steroids were chosen in most patients in this study be-
cause of difficulties in attending frequent clinic visits. In pa-
tients with a mild to moderate course, prednisolone was start-
ed at a lower dose (40 mg for 2 weeks) if they were in an ac-
tive stage and reported a recent aggravation of ocular symp-
toms and signs. 
Retrobulbar radiotherapy was not administered in this 
series. If activity reappeared, prednisolone was again given 
in the same manner. Rehabilitative surgery was only per-
formed in patients with inactive TAO (clinical activity score 
<3) for at least 6 months.
Statistical analysis
Demographic, clinical, and biochemical variables between 
patients with mild to moderate courses of TAO and severe 
courses of TAO, and between patients with and without com-
pressive optic neuropathy, were compared using independent 
t-tests for continuous variables and chi-square or Fisher’s ex-
act tests for categorical data. 
Multivariate logistic regression was performed to inves-
tigate the influence of age, gender, free T4 level (more than 3 
ng/dL), positive TBII level (more than 10 U/L), diabetes, and 
smoking status on both the severity of TAO and the develop-
ment of optic neuropathy. Odds ratios with 95% confidence 
intervals were calculated. All statistical analyses were per-
formed by a computer using SPSS ver. 12.0 (SPSS, Inc., 
Chicago, IL, USA).
Results
Out of a total of 99 patients who were eligible for analysis, 
83 were diagnosed with mild to moderate TAO and 16 were 
diagnosed with severe TAO. Demographic, clinical, and bio-
chemical features were compared between patients with mild 
to moderate TAO and severe TAO (Table 1). There were old-
er patients among those with severe courses than in the group 
with mild to moderate courses (t-test, p = 0.007). There were 
more male patients in patients with a severe course (43.8%) 
compared to those with a mild to moderate course (20.5%); 
however, this difference was not statistically significant 
(chi-square test, p = 0.060). There was no statistically sig-
nificant difference between the two groups with regard to 
length of the follow-up period (t-test, p = 0.967). The initial 
free T4 levels were high (above 3 ng/dL) in 30.0% of the JH Lee, et al. Risk Factor Analysis Associated with the Severity
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Table 3. Comparison of demographic, clinical, and biochemical features between patients with and without optic 
neuropathy
Without ON (n=90) With ON (n=9) p-value
Age (yr)     42 ± 14     50 ± 5 0.001
Male     20/90 (22.2)         4/9 (44.4) 0.214
Follow-up period for TAO (mon)      19.6 ± 19.5     20.1 ± 8.2 0.934
Initial fT4 level ≥3.0 ng/dL      22/76 (28.9)         2/8 (25.0) 1.000
Positive TBII (>0 U/L)      55/63 (87.3)         6/7 (85.7) 1.000
Comorbidity 
    Diabetes
    Hypertension
   3/90 (3.3)
   3/90 (3.3)
        2/9 (22.2)
        2/9 (22.2)
0.064
0.064
Current smoker      18/90 (20.0)         6/9 (66.7) 0.006
Exophthalmos (mm)     18.3 ± 2.8     20.7 ± 2.9 0.018
Lid retraction    52/90 (57.8)         5/9 (55.6) 1.000
Gorman score ≥2      19/90 (21.1)         5/9 (55.6) 0.036
Restrictive myopathy ≥-3      5/90 (5.6)         1/9 (11.1) 0.444
Clinical activity score ≥3  
Clinical activity score 
   14/90 (15.6)
      1.1 ± 1.2
        7/9 (77.8)
      3.9 ± 2.2
<0.001
0.005
Values are presented as mean ± SD or number/total number (%).
ON=optic neuropathy; TAO=thyroid-associated orbitopathy; TBII=thyroid binding-inhibiting immunoglobulin. 
Table 2. Variables predictive of the severity of thyroid-
associated orbitopathy on multiple logistic regression 
analysis
Variable p-value Odds ratio (95% CI)
Age 0.092 1.07 (0.99–1.15)
Gender 0.484 0.49 (0.07–3.56)
Free T4 ≥3.0 ng/dL 0.611 1.60 (0.26–9.71)
Positive TBII ≥10.0 U/L 0.464   2.57 (0.21–32.21)
Diabetes 0.616  2.36  (0.08–68.20)
Current smoker 0.032   6.57 (1.17–36.78)
TBII=thyroid binding-inhibiting immunoglobulin.
mild to moderate group and in 21.4% of the severe group. 
The ratio of patients with positive TBII was similarly high in 
both groups; 86.7% in the mild to moderate group and 90.0% 
in the severe group. However, there was no statistical sig-
nificance with respect to the number of patients with a high 
initial free T4 level (>3.0 ng/dL) and positive TBII (>10 U/L) 
between the two groups (chi-square test, p = 0.748; 
chi-square test, p = 1.000, respectively). More patients with 
a severe course had a history of diabetes (chi-square test, p =
0.029). More patients with a severe course were smokers 
compared to those with a mild to moderate course (chi-square 
test, p = 0.021). More patients with a severe course had a 
Gorman score of 2 or 3 (chi-square test, p = 0.036) and a 
higher clinical activity score (chi-square test, p <0 . 0 0 1 ;  
t-test, p = 0.005). There was no statistically significant dif-
ference in restrictive myopathy between the two groups 
(chi-square test, p = 0.444).
On multiple logistic regression analysis, smoking behavior 
was found to be a risk factor for severe TAO with an odds ra-
tio of 6.57 (Table 2). A history of diabetes and a positive TBII 
level also revealed odds ratios of 2.36 and 2.57, respectively; 
however, they were not statistically significant.
When demographic, clinical, and biochemical variables 
were compared in patients with and without optic neuro-
pathy, patients with optic neuropathy were older on average 
(t-test, p = 0.001) (Table 3). A higher ratio of the male gender 
was found in the group with optic neuropathy, but this differ-
ence was not statistically significant (chi-square test, p =
0.214). There was no significant difference between the two 
groups regarding the percentage of patients with a high initial 
free T4 level above 3.0 ng/dL and positive TBII (chi square 
test, p = 1.000). More patients with optic neuropathy had a 
history of diabetes and hypertension, but those differences 
were not statistically significant (chi-square test, p = 0.064). 
In addition, patients with optic neuropathy exhibited more 
exophthalmos (t-test, p = 0.018), a higher Gorman score of 2 
or 3 (chi-square test, p = 0.036), and a higher clinical activity 
score (t-test, p < 0.001) than those without optic neuropathy. 
Multiple logistic regression analysis revealed that smok-
ing influenced the development of optic neuropathy, with an 
odds ratio of 10.00 (Table 4). A history of diabetes, free T4 
level ≥3.0 ng/dL, and positive TBII had an odds ratio of 3.90, 
2.31, and 1.47, respectively, but they were not statistically 
significant. 
Discussion
The clinical diagnosis of TAO is relatively easy; however, 
clinical decisions regarding steroid treatment, irradiation, or 
surgical rehabilitation are often difficult. The natural course 
of TAO is benign in most patients and improvement is often 
seen with only conservative treatment. However, some pa-
tients develop progressive severe ophthalmopathy and re-
quire prolonged anti-inflammatory therapy. Clinical deci-
sions would be easier if the course of TAO could be predicted. Korean J Ophthalmol Vol.24, No.5, 2010
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Table 4. Variables predictive of optic neuropathy on multiple logistic regression analysis
Variable p-value Odds ratio (95% CI)
Age 0.064 1.10 (1.00 – 1.22)
Gender 0.314 0.30 (0.03 – 3.12)
Free T4 ≥3.0 ng/dL 0.472 2.31 (0.24 – 22.75)
Positive TBII ≥10.0 U/L 0.779 1.47 (0.10 – 21.84)
Diabetes 0.472   3.90 (0.10 – 158.94)
Current smoker 0.033 10.00 (1.20 – 83.50)
TBII = thyroid binding-inhibiting immunoglobulin.
Several risk factors including old age, male gender, smok-
ing, and abnormal thyroid function have been identified in 
several reports as possible predisposing factors for severe 
TAO. A positive relationship between age and ophthalmo- 
pathy index has been identified; also, males were found to 
have an average ophthalmopathy index 41% greater than that 
of females after correcting for age [14]. Several cross-sec-
tional and cohort studies have shown that smoking is an in-
dependent risk factor for severe ophthalmopathy [6,15-19]. 
One review journal provided strong evidence for a causal as-
sociation between smoking and the development of TAO, 
with a risk ratio/odds ratio >2 in most studies, although the 
quality of the studies varied [17]. Thyroid status was influen-
tial in determining the clinical course of ophthalmopathy in 
several reports [5,7,8,20-22]. In the past, euthyroid Graves’ 
disease was reported to be a predictor of poor prognosis in 
patients who receive orbital irradiation [22]. In one recent re-
port, patients in a normal thyroid function group were sig-
nificantly older, more likely to be male, and had less severe 
ophthalmopathy than did patients in an abnormal thyroid 
function group [5]. 
In our analysis, patients with severe TAO were older, more 
likely to have diabetes, and were more likely to be smokers 
than patients with mild to moderate courses of TAO. Thyroid 
status as assessed by the initial free T4 level, TBII, and TAO 
duration were not associated with severe TAO. Turning to the 
clinical features, patients with severe TAO showed a higher 
degree of exophthalmos, more severe diplopia, more severe 
restrictive myopathy, and higher clinical activity scores. 
However, in the multiple logistic regression analysis only 
smoking was predictive of severe TAO. 
TAO in patients with optic neuropathy is almost always ac-
tive and requires urgent treatment. It is essential that the cor-
rect diagnosis be made. In the European Group on Graves’ 
Orbitopathy survey, there was no defined gold standard for 
the diagnosis of optic neuropathy [23,24]. Three criteria in-
cluding radiologic evidence of optic neuropathy (apical 
crowding), reduced visual acuity, and impaired color vision 
were highly sensitive and specific in making a clinical diag-
nosis of optic neuropathy. In patients with a crowded apex on 
scanning, clinically diagnosed optic neuropathy was present 
in 88% of cases [23,24]. To better define this condition, 
Dayan and Dayan [23] recommended a diagnostic algorithm 
for optic neuropathy that included radiologic evidence of op-
tic nerve compression. Although this criteria is not always 
necessary in the definition of optic neuropathy [25], we be-
lieve radiologic assessment showing apical crowding or fat 
prolapse through the superior orbital fissure can confirm the 
presence of optic neuropathy and exclude alternative causes. 
Optic neuropathy has been found to be correlated with both 
total extraocular muscle volume and a limitation of ocular 
motility, which suggests that optic nerve involvement is 
more likely to occur in association with noncompliant fi-
brotic muscle versus more supple muscle of the same total 
volume [26]. Male gender, old age, diabetes, and heavy 
smoking were reported as other risk factors [9].
In our series, age, smoking, exophthalmos, myopathy, and 
CAS were found to be related to the development of optic 
neuropathy. The absence of severe proptosis in dysthyroid 
optic neuropathy patients has previously been reported [27]. 
A lack of proptosis could increase orbital pressure, preci- 
pitating optic neuropathy in some cases [28]. However, in 
our study, patients with optic neuropathy exhibited greater 
exophthalmometry than patients without optic neuropathy (p
= 0.018). This could result from the inclusion of patients 
with a mild to moderate course into the group without optic 
neuropathy. If the comparison was confined to patients with a 
severe course, the results could be similar to the previous 
reports. Among those patients, smoking was the only pre-
dictive factor of optic neuropathy, with an odds ratio of 10.00 
(p = 0.033). 
A number of experimental and clinical studies support the 
idea that TSH-receptor autoantibodies, such as the TBII or 
thyroid-stimulating antibody, are involved in the pathophysi-
ology of TAO [29-31]. In one study of Asian patients, the lev-
el of thyroid-stimulating autoantibodies and the absence of 
anti-thyroid peroxidase antibodies were independent risk 
factors for TAO, whereas no correlations between TBII or 
anti-thyroglobulin antibody levels and ophthalmopathy were 
found [30]. In our study, TBII levels were frequently positive 
(more than 10 U/L) in both the mild to moderate and severe 
groups (86.7% and 90.0%, respectively), but this difference 
was not statistically significant.
We have confirmed that smoking is the strongest risk fac-
tor for development of a severe course of TAO and optic neu-
ropathy in Korean patients, as observed in previous studies 
[6,15-19]. In an in vitro model of TAO, cigarette smoke ex-
tract increased glycosaminoglycan production and adipo-JH Lee, et al. Risk Factor Analysis Associated with the Severity
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genesis in orbital fibroblasts [32]. Thus, it is important for 
patients with Graves’ disease to refrain from smoking. In ad-
dition, frequent and careful observation should be performed 
in current smokers, as patients who smoke are susceptible to 
a more severe course of TAO and/or optic neuropathy.
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